MFSD4A

Across TCGA pan-cancer cohorts, MFSD4A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFSD4A data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MFSD4A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MFSD4A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MFSD4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.979	0.228	.007	20	view →
LUAD	OS	Tertile	III,IV	0.755	0.355	.010	19	view →
PDAC	OS	Quartile	All	0.976	0.395	.013	14	view →
LSCC	OS	Tertile	II,III,IV	0.262	0.918	.038	4	view →
GBM	DFS	Quartile	All	0.875	0.633	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MFSD4A–CCRCC (OS)

Open the CCRCC breakdown →